bluebird bio Inc

Most Recent

  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for Celgene in 2017

    Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.

    By Daniel Collins
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    XBI Rises in Contrast to a Flat Market

    XBI closed at $68.65 on November 17, 2015. Out of XBI’s 101 holdings, 70 stocks ended with positive returns, while 31 stocks ended in the red.

    By Peter Neil
  • uploads///BGNE
    Company & Industry Overviews

    Do Analysts See Any Upside in BeiGene Stock?

    Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    BLUE Is IBB’s Worst-Performing Small-Cap on Disappointing Data

    On December 7, 2015, bluebird bio (BLUE) fell 37.6%. The stock fell after it announced disappointing clinical data for its BB305 treatment.

    By Peter Neil
  • uploads///ousa chea  unsplash
    Healthcare

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio stock has risen ~119.9% over the last 12 months and 6.3% year-to-date.

    By Mike Benson
  • uploads///Graph Part
    Company & Industry Overviews

    XBI’s Moving Averages: The Massive Plummet Last Week

    XBI’s moving average took a hit in the week ended September 25, and most of its stocks were trading below all the moving averages. Compared to the previous week, the fall was massive.

    By Peter Neil
  • uploads///Yescarta
    Company & Industry Overviews

    What Else Could Drive Gilead’s Long-Term Growth?

    In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.

    By Daniel Collins
  • uploads///Graph Part
    Company & Industry Overviews

    Biotech Stocks Hammered Badly Last Week after Clinton Comment

    Last week was an unforgettable week for biotech stocks. It began on a bad note after Hillary Clinton commented on price controls for the specialty drug market, which created panic and triggered a sell-off.

    By Peter Neil
  • uploads///AdobeStock_
    Healthcare

    Will Genocea Stock Bounce Back? In-Depth Analysis

    Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.

    By Oleksandr Pylypenko
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Commodities Fell, XBI Was the Weaker Biotech ETF

    For the week ending December 11, most of the biotech stocks and ETFs were in the red. The SPDR S&P Biotech ETF (XBI) was the worst. It had a return of -6.5%.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Most Analysts Have Given bluebird bio Positive Ratings in March

    Wall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing price on March 27.

    By Margaret Patrick
  • uploads///SGMO net loss
    Company & Industry Overviews

    How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

    In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

    By Daniel Collins
  • uploads///Sangamo
    Company & Industry Overviews

    A Financial Overview of Sangamo Therapeutics in December 2018

    In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.

    By Daniel Collins
  • uploads///cells _
    Company & Industry Overviews

    Taking Stock of BeiGene’s Latest Performance

    BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Do Analysts See Any Upside for bluebird bio Stock?

    In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Understanding bluebird bio’s Operational Performance

    In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///EDIT
    Company & Industry Overviews

    Editas Stock: Analysts’ Recommendations

    In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    Analysts Expect Incyte to Report Revenue Growth in Third Quarter

    Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///regenxbio ana reco
    Company & Industry Overviews

    Analyzing Regenxbio’s Valuation Metrics

    Regenxbio (RGNX) generated revenues of $40.03 million in the second quarter compared to $6.56 million in Q2 2017.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.

    By Mike Benson
  • uploads///hospital _
    Company & Industry Overviews

    Bluebird Bio’s Valuation on September 6

    Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///dna _
    Earnings Report

    What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

    Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Bluebird Bio Stock

    As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.

    By Mike Benson
  • uploads///bb
    Company & Industry Overviews

    Celgene’s CAR T Cell Therapy Could Be Long-Term Growth Driver

    In June 2018, Celgene (CELG) and Bluebird Bio (BLUE) presented updated results from the ongoing phase 1 CRB-401 trial of bb2121.

    By Daniel Collins
  • uploads///cell
    Company & Industry Overviews

    Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18

    On June 18, Actinium Pharmaceuticals (ATNM) stock rose ~25.6% to reach $0.63.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Intellia Therapeutics Stock Fell 9.8% on Monday

    On June 11, Intellia stock fell 9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.

    By Mike Benson
  • uploads///versartis
    Company & Industry Overviews

    Versartis Stock and Its Consistent Rise in the Week Ended June 8

    Versartis (VSAR) stock rose 48.3% in the week of June 1–8. On June 8, it closed at $2.15.

    By Daniel Collins
  • uploads///Omeros
    Company & Industry Overviews

    Why Omeros Stock Rose Last Week

    On April 2, 2018, Omeros (OMER) stock opened at $11.12. It grew ~22% over the week to close at $13.58 on April 6.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?

    On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53.

    By Daniel Collins
  • uploads///AKCA
    Company & Industry Overviews

    Exploring the Financial Performance of Akcea Therapeutics

    In 2017, Akcea Therapeutics (AKCA) generated total revenue of $55.2 million.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Analysts’ Recommendations for Akcea and Its Peers in March

    Akcea Therapeutics is currently advancing a mature pipeline of four novel drugs with the potential to treat many cardiometabolic diseases.

    By Kenneth Smith
  • uploads///cell therapy
    Company & Industry Overviews

    Cell Therapy Market Could Boost Celgene’s Long-Term Growth

    With the acquisition of Juno Therapeutics, Celgene will benefit from all of Juno Therapeutics’ facilities related to cell therapy.

    By Daniel Collins
  • uploads///Celgene Strategy
    Company & Industry Overviews

    Behind Celgene’s Strategy in the Juno Therapeutics Acquisition

    With the acquisition of Juno Therapeutics (JUNO), Celgene (CELG) will likely become an established cellular immunotherapy company.

    By Daniel Collins
  • uploads///Strensiq Revenues
    Company & Industry Overviews

    Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017

    In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.

    By Daniel Collins
  • uploads///Genzyme
    Earnings Report

    A Look at Prospects for Genzyme, a Sanofi Company

    Following its acquisition in 2011, Genzyme became a wholly owned subsidiary of Sanofi (SNY).

    By Jillian Dabney
  • uploads///Graph naglazyme
    Company & Industry Overviews

    Naglazyme: One of the Costliest Drugs in the United States

    The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.

    By Jillian Dabney
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    IBB Leads Biotech ETFs with Rise of 3.1%

    Markets rose in the week ended November 20, as many believed the FED will hike the interest rate in December. The iShares Nasdaq Biotechnology ETF (IBB) rose 3.1%.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Medivation and Bluebird Led IBB’s Mid-Cap Stocks Last Week

    Medivation and Bluebird led IBB’s mid-cap stocks for the week ended September 18, 2015.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    XBI’s Top Ten Small-Caps Outperform IBB’s Top Ten Small-Caps

    Within the SPDR S&P Biotechnology ETF (XBI), ZIOPHARM Oncology (ZIOP) rose 18.55% for the week ending September 18.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    XBI Stocks: 33% Are Trading above the 20-Day Moving Averages

    XBI fell substantially in the moving averages. From August 10–17, 2015, only 32.63% of the stocks were trading above the 20-day moving averages.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.